{"entity":{"id":"beijing-gene-key-life-technology","kind":"company","name":"Beijing Gene Key Life Technology","aka":["Beijing Gene Key Life Technology Co., Ltd"],"tldr":"Beijing Gene Key Life Technology is a Chinese developer in Beijing that sponsors 2 registered cancer trials of GKL-006.","summary":"Beijing Gene Key Life Technology appears on ClinicalTrials.gov as the industry sponsor of 2 interventional cancer trials (phase 1/2, 2), testing GKL-006 in hepatocellular carcinoma (hcc), unresectable hepatocellular cancer, advanced pancreatic cancer, ductal adenocarcinoma of pancreas. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials sponsored by Beijing Gene Key Life Technology","url":"https://clinicaltrials.gov/search?spons=Beijing%20Gene%20Key%20Life%20Technology"}],"tags":["ctgov-sponsor","china","registry-only"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07209813","nct07777211"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"hq":"Beijing, China","country":"CN","companyType":"biotech","investors":[],"funding":[]},"route":"/companies/beijing-gene-key-life-technology/","neighbours":{"trial":[{"id":"nct07777211","kind":"trial","name":"A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer","route":"/trials/nct07777211/"},{"id":"nct07209813","kind":"trial","name":"GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma","route":"/trials/nct07209813/"}]}}